Contemporary Guidelines for Menopausal Health

Menopausal care has undergone a significant transformation over the past two decades, evolving from a symptom-centric approach to a comprehensive, evidence-based, and individualized model of care. This shift has been driven by advances in clinical research, an enhanced understanding of women’s health needs, and a global movement toward personalized patient care. Clinical Practice Guidelines (CPGs) have been central to this progress, emphasizing shared decision-making, risk stratification, and the appropriate timing and route of therapy rather than uniform treatment algorithms. This supplement of the Indian Menopause Society’s CPGs aims to translate this evolving evidence into pragmatic care pathways applicable across India’s diverse healthcare settings.[1,2] Guidelines are rigorously developed, evidence-based statements that guide clinicians and patients toward informed decision-making in specific clinical scenarios. In menopausal care marked by heterogeneity in symptoms, cultural perceptions, and risk profiles, such guidelines offer a dependable, structured, and adaptable framework to support optimal clinical practice. Medical guidelines ensure quality, consistency, and safety in clinical care. By consolidating available evidence, evaluating benefits and harms, and presenting pragmatic recommendations, guidelines help reduce practice variation and promote high-quality, standardized management. They improve patient outcomes by endorsing effective interventions – such as menopausal hormone therapy (MHT) for vasomotor symptoms and also showing drawbacks. The role of lifestyle medicine is also gaining its due place in the menopause toolkit.[3] From a health systems perspective, guidelines contribute to cost-effective care by helping clinicians choose appropriate investigations and treatments. They also provide medicolegal protection by offering rational, research-backed pathways for decision-making. For clinicians, guidelines are an invaluable tool for continuous professional development, particularly in rapidly evolving fields of menopausal medicine.[4] Managing menopause is a global issue with local realities. Menopause is a physiological milestone with profound implications for a woman’s physical, psychological, and metabolic health. The post-Women’s Health Initiative era led to major paradigm shifts in understanding the benefits and risks of MHT, prompting updated guidelines worldwide.[5] While international guidelines draw upon evidence from large multicentric cohorts, Indian guidelines contextualize these recommendations to suit the unique demographic, nutritional, and epidemiological landscape of Indian women. Earlier menopause, higher metabolic risk, Vitamin D deficiency, and varied access to healthcare necessitate tailored recommendations. Periodical updates improve credential of guidelines. Let us review major international guidelines. The North American Menopause Society (NAMS), 2023: The NAMS statement emphasizes individualized therapy, confirming that MHT remains the most effective treatment for vasomotor symptoms. It endorses the timing hypothesis, supports low-dose and transdermal regimens to minimize risk, and highlights nonhormonal alternatives for women with contraindications.[6] International Menopause Society, 2024 advocates a holistic approach, integrating lifestyle modifications, cardiovascular risk screening, and shared decision-making. Regular re-evaluation of therapy every 1–2 years is recommended. National Institute for Health and Care Excellence Guidelines (UK), NG23 Updated 2024: NICE prioritizes patient-centered counseling and risk assessment. Key features include MHT for vasomotor and urogenital symptoms, transdermal preparations for women at venous thromboembolism risk, and no mandatory age-based discontinuation.[7] European Menopause and Andropause Society (EMAS), 2023: EMAS focuses on cardiometabolic and bone health, encourages micronized progesterone and nonoral estrogen, and promotes multidisciplinary menopausal care. European Society of Endocrinology, 2025: The Endocrine Society supports MHT for specific symptomatic patients and for premature ovarian insufficiency until the physiological age of menopause and highlights the protective effects of early initiation. INDIAN GUIDELINES Indian Menopause Society, 2019 and 2023: Indian guidelines reflect the reality of earlier menopause (<46 years), high prevalence of Vitamin D deficiency, and increased cardiometabolic burden.[8] Key recommendations include: Comprehensive metabolic, skeletal, and cardiovascular assessment MHT for symptomatic women, ideally initiated <60 years or within 10 years of menopause Detailed baseline evaluation before initiating therapy Strong emphasis on lifestyle modification and nonhormonal options Attention to sarcopenia, Vitamin D deficiency, and metabolic syndrome Culturally sensitive counselling to dispel myths Use of local estrogen for urogenital symptoms. Federation of Obstetric and Gynaecological Societies of India (FOGSI), 2023: FOGSI integrates menopause into mainstream women’s health care, stressing individualized MHT use, metabolic and bone health screening, judicious use of bioidentical preparations with medical supervision, and training for OBGYNs and primary care physicians in menopause management.[9] Indian Council of Medical Research (ICMR), 2022: ICMR highlights research gaps and advocates long-term studies on Indian women’s MHT outcomes, national menopause registries, regional epidemiological research to refine guidelines, and policy frameworks for primary-care integration. PATH AHEAD Region-specific algorithms considering nutritional and socioeconomic diversity Training programs for primary care physicians specializing in menopausal medicine Digital platforms for teleconsultation, symptom tracking, and patient education Indian cohort studies on long-term effects of MHT in populations with diabetes, cardiovascular risks, and bone loss Integration of menopause into national health policy frameworks Role of AI in future menopausal management.[10,11] In Conclusion, menopausal health must be guided by robust, context-sensitive clinical guidelines. While international recommendations provide scientific rigor, Indian guidelines ensure that care is culturally relevant, equitable, and aligned with local epidemiology. A hybrid model – global evidence adapted to local needs – remains the cornerstone of optimal menopausal care. The present supplement of upgraded guidelines by the Indian Menopause Society will be an important document for menopausal medical practice, especially in the Asia-Pacific region. This commendable initiative reflects the collective dedication of the task force authors and the Indian Menopause Society toward advancing evidence-based, accessible, and woman-centered care for women in midlife.